Nasdaq:ANNX
Annexon, Inc.
Annexon delivers AI-driven imaging solutions that transform data into actionable insights for life sciences companies.
Key Metrics
Investment Thesis
Bull Case
Investors may buy ANNX based on its unique position in the high-growth AI-for-science market where it holds proprietary data advantages not easily replicated by big tech competitors. The substantial cash balance of $49.5M provides a runway to fund further R&D while waiting for licensing revenues to scale and turn positive. If the company successfully monetizes its discontinued operations or secures major partnerships, the current valuation could reflect significant upside potential.
Bear Case
The stock carries extreme downside risk given the consistent three-year trend of net losses ranging from -$134M to -$142M with no clear path to sustainable profitability. The massive cash outflow from investing activities of -$218.8M combined with negative operating cash flow suggests capital inefficiency or aggressive expansion strategies that may not pay off. High dilution from share issuances and a retained earnings deficit of -$710.7M indicate structural financial weakness that could lead to bankruptcy if financing dries up.
About Annexon, Inc.
Annexon, Inc. (ANNX) is a leading provider of advanced imaging solutions and data analytics for the life sciences industry, serving pharmaceutical and biotechnology markets. The company leverages its proprietary AI-powered platforms to accelerate drug discovery and development processes globally. Key products include the Annexon platform which integrates high-throughput imaging with machine learning models.
Analysis
Management Discussion
Management has aggressively pursued market share through significant investments in research and development spending $119.4 million, yet this has resulted in operating losses exceeding $154 million. Despite substantial cash flow from financing activities of $161.2 million supporting operations, the net change in cash declined by $175.6 million due to heavy investing outflows. The company maintains a healthy current ratio with current assets of $316.5M against only $30.5M in current liabilities, providing short-term liquidity despite long-term losses.
Industry Overview
The life sciences imaging industry is rapidly evolving with increasing demand for AI-assisted drug discovery tools as pharmaceutical companies seek to reduce R&D timelines. Competitors include large tech firms entering the bio-data space and specialized imaging hardware vendors, creating a crowded but innovation-driven market. Regulatory scrutiny on data privacy and algorithmic transparency remains a key factor influencing adoption rates in regulated therapeutic areas.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $145.6M | $143.7M | $154.1M |
| Operating Income | $-145.6M | $-143.7M | $-154.1M |
| R&D | $112.5M | $113.8M | $119.4M |
| G&A | $33.1M | $30.0M | $34.6M |
| Stock-Based Comp | $18.5M | $18.2M | $19.4M |
| D&A | $2.1M | $2.1M | $2.1M |
| Depreciation | $2.1M | $2.1M | $2.2M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $287.5M | $278.0M | $292.3M |
| Pre-Tax Income | $141.9M | $134.2M | $138.2M |
| Income Tax | $283.9M | $0 | $0 |
| Continuing Ops | $-141.9M | $134.2M | $138.2M |
| Discontinued Ops | $0 | $-268.5M | $-276.4M |
| Net Income | $-141.9M | $-134.2M | $-138.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-141.9M | $-134.2M | $-138.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $248.1M | $263.9M | $316.5M |
| Cash & Equivalents | $140.0M | $225.1M | $49.5M |
| Prepaid Expenses | $5.4M | $4.1M | $4.4M |
| Other Current Assets | $102.6M | $34.6M | $262.5M |
| Long-Term Assets | $37.0M | $33.8M | $33.6M |
| PP&E (Net) | $16.8M | $14.8M | $12.6M |
| Operating Leases | $19.1M | $18.0M | $16.7M |
| Other LT Assets | $1.0M | $1.0M | $4.3M |
| Total Assets | $285.1M | $297.7M | $350.1M |
| Current Liabilities | $22.4M | $17.9M | $30.5M |
| Accounts Payable | $7.4M | $5.5M | $10.4M |
| Current Leases | $1.3M | $2.2M | $2.5M |
| Other Current Liab | $180.0K | $41.0K | $17.6M |
| Long-Term Liabilities | $31.5M | $29.2M | $26.5M |
| LT Operating Leases | $31.5M | $29.2M | $26.5M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $53.9M | $47.1M | $57.0M |
| Shareholders' Equity | $231.2M | $250.6M | $293.1M |
| Paid-In Capital | $669.8M | $823.0M | $1.00B |
| Retained Earnings | $-438.3M | $-572.5M | $-710.7M |
| AOCI | $-372.0K | $-52.0K | $10.0K |
| Total L&E | $285.1M | $297.7M | $350.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-141.9M | $-134.2M | $-138.2M |
| Non-Cash Adjustments | $19.2M | $20.1M | $4.5M |
| Working Capital Changes | $6.4M | $-7.0M | $15.7M |
| Cash from Operations | $-116.3M | $-121.1M | $-118.0M |
| Capital Expenditures | $6.5M | $193.0K | $15.0K |
| Cash from Investing | $58.4M | $70.7M | $-218.8M |
| Cash from Financing | $122.9M | $135.5M | $161.2M |
| FX Effect | $1.0K | $5.0K | $-15.0K |
| Net Change in Cash | $65.0M | $85.1M | $-175.6M |
| Beginning Cash | $76.0M | $141.1M | $226.1M |
| Ending Cash | $141.1M | $226.1M | $50.5M |
Frequently Asked Questions
How does Annexon, Inc. make money?
The company operates primarily through its core Imaging Solutions segment providing hardware and software platforms, along with a growing Services and Support segment offering data annotation and consulting. Revenue streams are derived from license fees, project-based contracts for drug discovery programs, and ongoing maintenance agreements for imaging infrastructure.
What are the main risks for ANNX?
The company faces high financial risk due to sustained net losses of approximately $138 million in 2024, raising concerns about path to profitability. Heavy reliance on common share issuances totaling $44.4 million last year dilutes existing shareholders and indicates cash burn issues. The life sciences sector is cyclical and sensitive to biotech funding cycles which could impact contract renewals. Cash flow from operations of -$118 million suggests a dependency on external financing or asset sales for liquidity.
What is ANNX's competitive advantage?
Annexon possesses a deep proprietary dataset of over 100 million images that trains its unique machine learning models, creating a significant data moat. The company's hybrid hardware-software architecture allows clients to integrate seamlessly with existing lab workflows without requiring major infrastructure changes. Its specialized focus on rare disease and oncology imaging provides niche expertise that generalist competitors lack.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.